Mr. Needleman stated:

"The purpose of the SAB is to identify whatever gaps there are in our offerings and to proactively suggest solutions. In analyzing what Aptuit is doing as a company, we want to be sure that every effort is being made to improve and enhance our service."

SAB board members were selected from Aptuit’s network of global facilities. They represent scientists with uncommon expertise who have contributed to the delivery of exceptional result for our clients. The newly named SAB includes:

John Masters, Ph.D., Director of Business Development & Strategic Alliances, as Chairman. Other appointees are: Sergio Raimondo, E.RT., Head of Toxicology & Pathology and Director of GLP Testing Facilities; Romano Di Fabio, Ph.D., Scientific Director, Drug Design & Discovery; Mauro Corsi, Ph.D., Director of Assay Development and In Vitro Profiling; Susan Bogdanowich-Knipp, Ph.D., Director, Analytical Research; Dave Engers, Ph.D., Director, Chemistry; Marcello DiMare, Ph.D., Senior Director, API, Chemistry; Jean Francois Carniaux, Ph.D., Director, API, Chemical Development and Production Laboratories; and Sarah Eccleston, Ph.D., Head of Technical Development at Aptuit’s Glasgow site.

According to its Charter, the Board is charged with reviewing current scientific issues that challenge the pharmaceutical and CRO industries and with identifying potential challenges that might impact Aptuit’s future. The SAB will consider and advise senior management regarding the launch of new capabilities and technologies and provide input on the potential of strategic acquisitions and partnerships.

They will determine the market demand and financial implications for new initiations. The SAB will also be responsible for suggesting future scientific capital expenditures, providing both scientific and business rationales for their implementation. Members will be encouraged to present their own questions and recommendations that can advance Aptuit’s scientific future.

Mr. Needleman concluded:

"We are optimistic that our SAB will identify the scientific initiatives that will advance our goals. Their recommendations for amassing new technologies will further enhance the Uncommon Expertise that we have assembled. We have been achieving Exceptional Results for our clients, and we want to exceed their expectations as well as our own confidence in the future, securing our role as the leading provider of drug discovery and development services."